• 1
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47(1):8187.
  • 2
    Jaeschke R, Guyatt GH, Keller J, Singer J. Interpreting changes in quality-of-life score in N of 1 randomized trials. Control Clin Trials 1991;12(Suppl 4):226S233S.
  • 3
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2(2):113127.
  • 4
    Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality of life research. How meaningful is it? Pharmacoeconomics 2000;18(5):419423.
  • 5
    Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37(5):469478.
  • 6
    Juniper EF. Quality of life questionnaires: does statistically significant = clinically important? J Allergy Clin Immunol 1998;102(1):1617.
  • 7
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77(4):371383.
  • 8
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10(4):407415.
  • 9
    Barber BL, Santanello NC, Epstein RS. Impact of the global on patient perceivable change in an asthma specific QOL questionnaire. Qual Life Res 1996;5(1):117122.
  • 10
    Rector TS, Tschumperlin LK, Kubo SH, et al. Clinically significant improvements in the living with heart failure questionnaire score as judged by patients with heart failure. Qual Life Res 1994;3: 6061.
  • 11
    van Walraven C, Mahon JL, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample-size calculation. J Clin Epidemiol 1999;52(8):717723.
  • 12
    Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996;49(11):12151219.
  • 13
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 1998;16(1):139144.
  • 14
    Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2(3):221226.
  • 15
    Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. Value Health 2001;4(2):178.
  • 16
    Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59(1):1219.
  • 17
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104(12):13741379.
  • 18
    Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000;19(2):8391.
  • 19
    van Kerrebroeck P, Kreder K, Jonas U. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57(3):414421.
  • 20
    Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 1995;7(5):404408.
  • 21
    Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999;83(6):583590.
  • 22
    Reese PR, Pleil AM, Okano GJ, Kolleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003;12: 427442.
  • 23
    Okano GJ, Pleil AM, Reese PR, Kelleher CJ. Effects of long-term tolterodine treatment on physical and symptom aspects of health-related quality of life in overactive bladder patients. Value Health 2002;5(3):278.
  • 24
    Pleil AM, Reese PR, Okano GJ, Kelleher CJ. Validation of King's Health Questionnaire in patients with symptoms of overactive bladder. Qual Life Res 2000;9(3):347.
  • 25
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder Am J Manag Care 2002;8(19):S608S615.
  • 26
    Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 2000;6(1):3949.
  • 27
    Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15(2):141155.
  • 28
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1998.
  • 29
    Mangione C, Lee PP, Coleman AL, Shapiro MF, Berry S, Keeler E. Responsiveness of the NEI VFQ-25 to Cataract Surgery. 13 November 2000.
  • 30
    Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997;50(8):869879.
  • 31
    Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001;39(10):10391047.
  • 32
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Massachusetts: The Health Institute, New England Medical Center, 1993.
  • 33
    Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 1999;53(1):7176.